Business
Directorate Change
Directorate Change.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 2412T Oxford Biomedica PLC 02 July 2018 \n\n \n \n \n \n \n \nDirectorate Change\n \nLondon, UK - 02 July 2018: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, today announces, as previously stated on 4 June 2018, Peter Nolan has retired from his role as Chief Business Officer and has stepped down from the Board. \n- Ends -\n \n \n\n\n\n\nFor further information, please contact:\n \n\n\n \n\n\n\n\nOxford BioMedica plc: Tel: +44 (0)1865 783 000\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\n \nFinancial PR Enquiries: Tel: +44 (0)20 3709 5700\nConsilium Strategic Communications\nMary-Jane Elliott / Matthew Neal /\nOliver Manser / Laura Thornton\n \nPeel Hunt (Joint Corporate Broker): Tel: +44 (0)20 7418 8900\nJames Steel / Dr. Christopher Golden\n \nWG Partners (Joint Corporate Broker): Tel: +44 (0)20 3705 9321\nDavid Wilson / Claes Spång\n \n \nNotes for editors\n \n \nAbout Oxford BioMedica\nOxford BioMedica (LSE...